US Edition
Published • loading... • Updated
Transcenta Therapeutics in Princeton appoints Hwang to head of global partnerships
Summary by ROI-NJ
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Transcenta Therapeutics in Princeton appoints Hwang to head of global partnerships
Transcenta Therapeutics, a global clinical-stage biopharmaceutical company with a clinical development center in Princeton, announced the appointment of Dr. Christopher Hwang as head of global partnerships for its Highly Intensified Continuous Bioprocessing (HiCB) platform, leading the execution of its global technology out-licensing strategy. Hwang holds a Ph.D. in biochemical engineering from Massachusetts Institute of Technology (MIT) and bri…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
